This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

ANTHONY V. PISCIOTTA, M.D.

AMA Arch Intern Med. 1959;104(2):264-276.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

During the past 50 years, an abundant literature has been directed to various aspects of autoimmune hemolytic disease. Recognition and measurement of changes in erythrocyte life span,¹ improved methods for demonstration of erythrocyte autoantibody,² and advances in knowledge of bile pigment metabolism ³ have facilitated diagnosis and understanding of this disorder. Fortunately, most clinical and hematologic manifestations of autoimmune hemolytic disease are correctible by treatment with the corticosteroids,^4,5 even though evidences of autosensitization of erythrocytes may persist. On the other hand, the existence of inordinately severe cases which prove resistant to therapy have provided further opportunity to observe the natural course of the disease. We have studied a patient in whom continuous production of autoantibody in high titer resulted in constant anemia, reticulocytosis, and icterus, despite intensive treatment with corticosteroids. These exaggeratedly abnormal laboratory values lent themselves particularly well to a study of the effects of "autosensitization" . . . [Full Text PDF of this Article]

Author Affiliations
Milwaukee With the Technical Assistance of Estelle M. Downer, M.S., and Jean E. Hinz, A.B.

From the Hematology Service, Department of Internal Medicine, Marquette University School of Medicine and Milwaukee County General Hospital.

Footnotes
Submitted for publication Sept. 30, 1958.

Aided by a Research Grant (A-1024) from the National Institute of Arthritis and Metabolic Diseases, National Institutes of Health, Public Health Service, U. S. Department of Health, Education and Welfare, Bethesda, Md., and with the assistance of a grant from the Committee on Research, Council on Pharmacy and Chemistry, American Medical Association.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?